KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares OutstandingShort-Term Debt issuances
Ratios

Bristol Myers Squibb (BMY) R&D In Process (2021 - 2025)

Historic R&D In Process for Bristol Myers Squibb (BMY) over the last 5 years, with Q3 2025 value amounting to $633.0 million.

  • Bristol Myers Squibb's R&D In Process rose 14160.31% to $633.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year decrease of 8308.11%. This contributed to the annual value of $13.4 billion for FY2024, which is 136473.17% up from last year.
  • As of Q3 2025, Bristol Myers Squibb's R&D In Process stood at $633.0 million, which was up 14160.31% from $1.5 billion recorded in Q2 2025.
  • In the past 5 years, Bristol Myers Squibb's R&D In Process registered a high of $12.9 billion during Q1 2024, and its lowest value of $6.0 million during Q1 2021.
  • Moreover, its 5-year median value for R&D In Process was $188.0 million (2025), whereas its average is $978.4 million.
  • As far as peak fluctuations go, Bristol Myers Squibb's R&D In Process skyrocketed by 1716533.33% in 2024, and later crashed by 9854.82% in 2025.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's R&D In Process stood at $89.0 million in 2021, then tumbled by 41.57% to $52.0 million in 2022, then surged by 1053.85% to $600.0 million in 2023, then tumbled by 95.0% to $30.0 million in 2024, then skyrocketed by 2010.0% to $633.0 million in 2025.
  • Its last three reported values are $633.0 million in Q3 2025, $1.5 billion for Q2 2025, and $188.0 million during Q1 2025.